Sean X. Zhang

Follow

Generating author description...

Common Coauthors
Commonly Cited References
Action Title Year Authors # of times referenced
+ PDF Chat Benchmarking Unsupervised Outlier Detection with Realistic Synthetic Data 2021 Georg Steinbuß
Klemens Böhm
2
+ A weighted Kendall's tau statistic 1998 Grace S. Shieh
1
+ Adaptive designs for dual-agent phase I dose-escalation studies 2013 Jennifer Harrington
Graham Wheeler
Michael Sweeting
Adrian Mander
Duncan I. Jodrell
1
+ A survey on unsupervised outlier detection in high‐dimensional numerical data 2012 Arthur Zimek
Erich Schubert
Hans‐Peter Kriegel
1
+ Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option? 2008 Franklin G. Miller
Steven Joffe
1
+ Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer 1990 John O’Quigley
Margaret S. Pepe
Lloyd D. Fisher
1
+ PDF Chat Simple algorithm portfolio for SAT 2011 Mladen Nikolić
Filip Marić
Predrag Janičić
1
+ Theoretical Foundations and Algorithms for Outlier Ensembles 2015 CharĆł C. Aggarwal
Saket Sathe
1
+ Ethics of Phase 1 Oncology Studies 2003 Manish Agrawal
Ezekiel J. Emanuel
1
+ PDF Chat Dose Escalation Methods in Phase I Cancer Clinical Trials 2009 Christophe Le Tourneau
J. Jack Lee
Lillian L. Siu
1
+ PDF Chat American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment 2014 Jeffrey S. Weber
Laura A. Levit
Peter C. Adamson
Suanna S. Bruinooge
Howard A. Burris
Michael A. Carducci
Adam P. Dicker
Mithat Gönen
Stephen J. O’Keefe
Michael A. Postow
1
+ Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical Trials 2004 Thomas G. Roberts
1
+ PDF Chat Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002 2005 Elizabeth Horstmann
Mary S. McCabe
Louise B. Grochow
Seiichiro Yamamoto
Larry Rubinstein
Troy Budd
Dale Shoemaker
Ezekiel Emanuel
Christine Grady
1
+ PDF Chat No free lunch theorems for optimization 1997 David H. Wolpert
William G. Macready
1
+ The performance of model-based versus rule-based phase I clinical trials in oncology 2016 Emilie M.J. van Brummelen
Alwin D. R. Huitema
Erik van Werkhoven
J. H. Beijnen
Jan H.M. Schellens
1
+ Isolation Forest 2008 Fei Tony Liu
Kai Ming Ting
Zhi‐Hua Zhou
1
+ PDF Chat Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms 2016 Maria Schwaederlé
Melissa Zhao
J. Jack Lee
Vladimir Lazar
Brian Leyland‐Jones
Richard L. Schilsky
John Mendelsohn
Razelle Kurzrock
1
+ PDF Chat An appraisal of drug development timelines in the Era of precision oncology 2016 Denis L. Jardim
Maria Schwaederlé
David S. Hong
Razelle Kurzrock
1
+ PDF Chat Is Participation in Cancer Phase I Trials Really Therapeutic? 2016 Jonathan Kimmelman
1
+ Hyperband: A Novel Bandit-Based Approach to Hyperparameter Optimization 2016 Lisha Li
Kevin Jamieson
Giulia DeSalvo
Afshin Rostamizadeh
Ameet Talwalkar
1
+ Risks and benefits of phase 1 oncology trials, 2001 through 2012. 2014 Yoko Fukuda
Erich Huang
Shanda Finnigan
S. Percy Ivy
Larry Rubinstein
Naoko Takebe
1
+ Hybrid Isolation Forest - Application to Intrusion Detection 2017 Pierre-François Marteau
Saeid Soheily-Khah
Nicolas BĂ©chet
1
+ Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non–Small Cell Lung Cancer 2017 Mahmoud Hashim
Boris M. Pfeiffer
R. Bartsch
Maarten J. Postma
Bart Heeg
1
+ PDF Chat Estimation of clinical trial success rates and related parameters 2017 Chi Heem Wong
Kien Wei Siah
Andrew W. Lo
1
+ PyOD: A Python Toolbox for Scalable Outlier Detection 2019 Yue Zhao
Zain Nasrullah
Zheng Li
1
+ PDF Chat AutoML: A survey of the state-of-the-art 2020 Xin He
Kaiyong Zhao
Xiaowen Chu
1
+ Phase I trials as valid therapeutic options for patients with cancer 2019 Jacob J. Adashek
Patricia LoRusso
David S. Hong
Razelle Kurzrock
1
+ Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine 2019 Jonathan Kimmelman
1
+ PDF Chat Ethical and Policy Issues for Seamless Phase I Oncology Trials 2019 Nora Hutchinson
Esther Vinarov
Alexia Iasonos
Jonathan Kimmelman
1
+ PDF Chat PyODDS: An End-to-end Outlier Detection System with Automated Machine Learning 2020 Yuening Li
Daochen Zha
Praveen Kumar Venugopal
Na Zou
Xia Hu
1
+ PDF Chat On hyperparameter optimization of machine learning algorithms: Theory and practice 2020 Li Yang
Abdallah Shami
1
+ PDF Chat Distributed Anomaly Detection Using Autoencoder Neural Networks in WSN for IoT 2018 Tie Luo
Sai Ganesh Nagarajan
1
+ PDF Chat Deep Learning for Anomaly Detection 2021 Guansong Pang
Chunhua Shen
Longbing Cao
Anton van den Hengel
1
+ A Large-scale Study on Unsupervised Outlier Model Selection: Do Internal Strategies Suffice? 2021 QuintĂ­n MartĂ­n MartĂ­n
Yue Zhao
Xiaorong Zhang
Leman Akoglu
1
+ Outlier Analysis 2013 CharĆł C. Aggarwal
1
+ Model Evaluation, Model Selection, and Algorithm Selection in Machine Learning 2018 Sebastian Raschka
1
+ How to Evaluate the Quality of Unsupervised Anomaly Detection Algorithms? 2016 Nicolas Goix
1
+ PDF Chat Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents 2012 Christophe Le Tourneau
Hui Gan
Albiruni R. Abdul Razak
Xavier PaolettĂ­
1
+ PDF Chat ADBench: Anomaly Detection Benchmark 2022 Songqiao Han
Xiyang Hu
Hailiang Huang
Minqi Jiang
Yue Zhao
1